SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

OFFICIAL TRUMP (TRUMP) is a cryptocurrency and operates on the Solana platform. OFFICIAL TRUMP has a current supply of 999,998,811.032761 with 281,866,747.320393 in circulation. The last known price of OFFICIAL TRUMP is 1.57555883 USD and is down -1.93 over the last 24 hours. It is currently trading on 744 active market(s) with $126,884,732.61 traded over the last 24 hours. More information can be found at https://gettrumpmemes.com/.

Trump For President

The TRUMP meme coin is drawing attention amid discussion of its steep decline from launch highs and allegations that Trump-linked insiders profited while retail holders lost money. Many traders call it a scam and expect further downside, while some remain bullish on accumulation or a possible short squeeze.

Occidental Petroleum Corp. engages in the exploration and production of oil and natural gas. It operates through the following segments: Oil and Gas, Chemical, and Midstream and Marketing. The Oil and Gas segment explores for, develops and produces oil and condensate, natural gas liquids, and natural gas. The Chemical segment manufactures and markets basic chemicals and vinyls. The Midstream and Marketing segment purchases, markets, gathers, processes, transports and stores oil, condensate, natural gas liquids, natural gas, carbon dioxide, and power. The company was founded in 1920 and is headquartered in Houston, TX.

Occidental Petroleum Corp.

OXYs breakout to a six-month high amid strength in oil stocks is drawing attention, with bullish call-option activity adding to the momentum. Traders are watching for follow-through, while others question why the shares have not tracked crude prices more closely and point to resistance ahead.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Stockholm, Sweden.

Spotify Technology S.A.

Spotify shares are rallying after its latest quarterly report, as subscriber growth, improving gross margin and a stronger profit outlook outweighed modest revenue and EPS misses. Traders are debating the disconnect between the headline misses and the positive market reaction, with many pointing to forward guidance as the key driver.

Blue Owl Capital, Inc. operates as an alternative asset management firm. It provides investors access to asset management capital solutions through its Direct Lending and GP Capital Solutions products. The company offers a platform of capital solutions to both middle market companies and large alternative asset managers. The company was founded by Doug Irving Ostrover, Michael Rees and Craig W.Packer in 2009 and is headquartered in New York, NY.

Blue Owl Capital Inc - Ordinary Shares - Class A

Blue Owls Q3 results and upbeat earnings-call outlook are driving attention, with traders highlighting fee and AUM growth, dividend coverage, and unearned-fee backlog as reasons for optimism. Some remain cautious about private-credit redemptions and whether fee growth is durable, while bullish traders see the results as a counterpoint to lingering sector concerns.

Blackstone, Inc. engages in the provision of investment and fund management services. It operates through the following segments: Real Estate, Private Equity, Credit and Insurance, and Hedge Fund Solutions. The Real Estate segment includes management of opportunistic real estate funds, Core+ real estate funds, high-yield real estate debt funds, and liquid real estate debt funds. The Private Equity segment consists of management of flagship corporate private equity funds, sector and geographically focused corporate private equity funds, core private equity funds, an opportunistic investment platform, a secondary fund of funds business, infrastructure-focused funds, a life sciences investment platform, a growth equity investment platform, a multi-asset investment program for eligible high net worth investors and a capital markets services business. The Credit and Insurance segment refers to Blackstone Credit, which is organized into two overarching strategies: private credit which includes mezzanine direct lending funds, private placement strategies, stressed and distressed strategies and energy strategies, and liquid credit which consists of CLOs, closed-ended funds, open ended funds and separately managed accounts. In addition, the segment includes an insurer-focused platform, an asset-based finance platform, and publicly traded master limited partnership investment platform. The Hedge Fund Solutions segment focuses on Blackstone Alternative Asset Management, which manages a broad range of commingled and customized hedge fund of fund solutions. It also includes a GP Stakes business and investment platforms that invest directly, as well as investment platforms that seed new hedge fund businesses and create alternative solutions through daily liquidity products. The company was founded by Stephen Allen Schwarzman in 1985 and is headquartered in New York, NY.

Blackstone Inc

Blackstones reported expectation that Anthropic could receive a speculative-grade credit rating, reversing its earlier outlook, has drawn attention amid scrutiny of AI financing risk. Traders debate whether the report intensified selling, while call-heavy options activity is viewed by some as positioning rather than a clear bullish bet.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Chevrons Q3 earnings beat, driven in part by strong refining margins and record U.S. refinery throughput, is the main catalyst. Traders are reacting bullishly to the results and call-heavy options activity, while some question whether the refining boost will last.

Pyth Network (PYTH) is a cryptocurrency launched in 2021and operates on the Solana platform. Pyth Network has a current supply of 9,999,981,857.422035 with 7,874,958,862.767691 in circulation. The last known price of Pyth Network is 0.06608465 USD and is up 1.61 over the last 24 hours. It is currently trading on 450 active market(s) with $21,484,088.50 traded over the last 24 hours. More information can be found at https://pyth.network/.

Pyth Network

Pyths Nasdaq data-distribution and broader real-world-asset push are fueling bullish discussion, alongside the DAOs policy directing product revenue toward PYTH reserve accumulation. Traders see these developments as strengthening the tokens demand story, while others point to weak price action and potential token-unlock selling pressure.

VXX tracks an index with exposure to futures contracts on the CBOE Volatility Index with average one-month maturity. Exposure resets daily.

Barclays Bank PLC - iPathÂ® Series B S&P 500Â® VIX Short-Term FuturesTM ETN

iPath S&P 500 VIX Short-Term Futures ETN

A rebound in volatility has put VXX in focus as traders weigh hedging for a possible market pullback amid broader uncertainty. Some see the move as the start of a sustained volatility breakout, while others expect a short-lived pop and point to VXXs futures-related decay as a reason to fade rallies.

Churchill Capital Corp. XI is a blank check company. It was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Michael Stuart Klein on June 4, 2025 and is headquartered in New York, NY.

Churchill Capital Corp XI - Ordinary Shares - Class A

CCXI is drawing attention as the public-market route to Agility Robotics and its humanoid-robotics business, with traders also comparing the companys prospects and valuation with rival Unitree. Bulls point to commercial deployments and major backers, while skeptics focus on operating losses, valuation, dilution and the risk of a post-SPAC selloff.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons strong third-quarter earnings beat is driving a sharp rally and a new 52-week high, with traders highlighting growth across Dupixent, Eylea HD and Libtayo. The reaction is broadly bullish, though some note that declining legacy Eylea sales and potential profit-taking could temper the momentum.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Boston Scientifics quarterly report and reduced full-year outlook are driving attention: despite a modest beat on revenue and adjusted EPS, the company cited disruption from a cyberattack and slowing growth, including weakness in key device franchises. Traders are largely reacting to the outlook with frustration and concern about further declines, while some see the steep selloff as an overdone dip-buying opportunity.

Intuitive Surgical vs. Boston Scientific: Which Stock Is a Better Buy Now?

Intuitive Surgical's surging robotic surgery demand and stronger earnings momentum make it a better buy than Boston Scientific despite its valuation premium.

JNJ's MedTech Segment Disappoints in Q3: Will Growth Rebound in Q4? 

J&J's MedTech growth slows in Q3 amid international market challenges and Abiomed weakness.

New Strong Sell Stocks for October 30th

BSX, NBHC and NMRK have been added to the Zacks Rank #5 (Strong Sell) List on October 30th, 2026.

Penumbra, Inc. Reports Third Quarter 2026 Financial Results

Penumbra, Inc. Reports Third Quarter 2026 Financial Results Penumbra, Inc. Reports Third Quarter 2026 Financial ResultsPR NewswireALAMEDA, Calif., Oct. 29, 2026 ALAMEDA, Calif., Oct. 29, 2026 /PRNewswire/ -- Penumbra, Inc.(NYSE: PEN), the world's leading thrombectomy company, today reported...

ISRG Sales Jump 22%: Can Growth Stay Ahead of Procedure Volumes?

Intuitive Surgical's third-quarter sales surged 22%, outpacing procedure growth. Can system placements, new technologies and recurring revenues offset pricing pressures?

BSX Q3 Earnings Call Flags Growth Challenges Through 2027

Boston Scientific faces a challenging 2027 as cybersecurity disruptions, EP and WATCHMAN weakness and China pricing pressures weigh on growth prospects.

These Analysts Revise Their Forecasts On Boston Scientific After Q3 Results

Boston Scientific beat Q3 estimates but cut FY26 guidance; Q4 forecasts missed expectations. Analysts adjusted price targets.read more...

BSX Stock Looks To Snap 3-Week Winning Streak: Analysts Downgrade Boston Scientific As Cyberattack And Slowing Growth Cloud Outlook

Equity

Boston Scientific’s weak outlook, cyberattack disruptions, and slowing Watchman and electrophysiology growth weighed on sentiment.


Boston Scientific (BSX) Q3 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

BSX Q3 Earnings Meet Estimates, Revenues Rise Y/Y, Stock Down

Boston Scientific's third-quarter revenues beat estimates, but contracting margins, weaker segment sales and reduced 2026 guidance weigh on shares.	

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Boston Scientific Corp.

Bullish Sentiment

<ul class="summary-bullets"><li>Despite beating Q3 earnings estimates, Boston Scientific faces growth concerns.</li><li>Jefferies downgraded the stock to ‘Hold,’ cutting its price target to $46 from $60.</li><li>JPMorgan downgraded Boston Scientific to ‘Neutral’ and pointed to delayed product programs.&nbsp;&nbsp;&nbsp;</li></ul><p>Boston Scientific Corp. (BSX) stock is on track to reverse a&nbsp; three-week winning streak as Wall Street turns cautious after its third-quarter (Q3) results and a weaker 2026 outlook. Jefferies and JPMorgan downgraded the stock, slashing price targets over cyberattack fallout, slowing product growth and a delayed pipeline that could affect its 2027 performance.&nbsp;</p><p><a href="https://stocktwits.com/symbol/BSX">Boston Scientific stock</a> edged up 0.4% overnight, ahead of Thursday. The stock has fallen more than 7% so far this week.&nbsp;</p><h2 class="st-heading-2">Jefferies Downgrades Boston Scientific As Growth Catalysts Fade</h2><p>Though Boston Scientific’s third-quarter (Q3) earnings beat expectations, concerns about slower business momentum, delayed product development milestones and the lingering effects of a cyber incident have clouded its near-term outlook.</p><p>Jefferies analyst Matthew Taylor cut the medical device maker's stock to ‘Hold’ from ‘Buy’ and slashed his price target to $46 from $60, implying only an 8% upside from the stock’s last closing price.&nbsp;</p><p>The analyst cited uncertainty surrounding pulsed field ablation (PFA) and Watchman products, alongside a challenging business outlook and a limited number of growth drivers expected in 2027. Taylor expects the shares to remain range-bound over the coming quarters, with opportunities for growth only emerging in 2028 and later.</p><h2 class="st-heading-2">JPMorgan Flags Broader Business Concerns For&nbsp;Boston Scientific</h2><p>JPMorgan also took a cautious stance, shifting its rating to ‘Neutral’ from ‘Overweight’ and cutting its price target to $46 from $56. The analyst acknowledged that investors expected adjustments to the company's guidance after a cyber incident in Q3. However, the firm believes the weaker outlook extends beyond conservative financial projections.</p><p>The analyst said Boston Scientific expects slower sales and earnings growth in 2027. Delays in several product development projects also raised concerns about the company’s ability to meet its goals. The company cut its full-year adjusted earnings outlook to $3.16 to $3.18 per share from its prior estimate of $3.28 to $3.32 per share.&nbsp;</p><p>Needham lowered its price target to $48 from $57 but maintained a ‘Buy’ rating. While the cyber incident had already led investors to anticipate weaker guidance, Needham said other developments in the report added to the negative outlook. The disruption is now expected to affect Q4 results as well. Meanwhile, growth in the Watchman business and electrophysiology products weakened again, even after accounting for the cyber-related impact.</p><h2 class="st-heading-2">BSX Stock: Retail View&nbsp;</h2><p>However, on Stocktwits, retail sentiment around the stock flipped to ‘bullish’ from ‘bearish,’ with 1,161% surge in message volume over the past 24 hours.&nbsp;</p><p>A user&nbsp;<a href="https://stocktwits.com/St0ckt0k101/message/667612197">said</a>, “gotta watch for more price cuts!! You know they're coming to bring this down some more. Long and CANNOT sell this low.”</p><p>BSX stock has crashed 55% year-to-date.&nbsp;</p><p>Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-cvna-stock-rising-8-overnight/cZUQO5PR9be">Why Is CVNA Stock Rising 8% Overnight?</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

 In this photo illustration, a smartphone displays the logo of Boston Scientific Corporation.

Boston Scientific Corp. (BSX) stock is on track to reverse a three-week winning streak as Wall Street turns cautious after its third-quarter (Q3) results and a weaker 2026 outlook. Jefferies and JPMorgan downgraded the stock, slashing price targets over c

iShares US Medical Devices ETF

Vanguard Group, Inc. - Vanguard U.S. Value Factor ETF

$OUST

$BSX

$ALAB

$CRCL

Which of these trending stocks are you most bullish on right now?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '26	$0.78	--	--	N/A
Q3 '26	$0.72	$0.73	1.62%	BEAT
Q2 '26	$0.83	$0.86	3.90%	BEAT
Q1 '26	$0.79	$0.80	1.51%	BEAT
Q4 '25	$0.78	$0.80	2.56%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

BSX Earnings

Latest Earnings Results: Q3 '26

Historical Earnings